MOXEZA

Peak

moxifloxacin hydrochloride

NDAOPHTHALMICSOLUTION/DROPS
Approved
Nov 2010
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1

Clinical Trials (1)

NCT05413980N/ACompleted

Effectiveness and Safety of 0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in Perioperative Sterilization in Patients Undergoing Ophthalmic Surgery

Started Jan 2024
102 enrolled
Post Operative Endophthalmitis

Loss of Exclusivity

LOE Date
May 29, 2029
39 months away
Patent Expiry
May 29, 2029

Patent Records (2)

Patent #ExpiryTypeUse Code
8450311
May 29, 2029
Product
—
9114168
May 29, 2029
Product
—
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers